Val M Runge

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11264640/publications.pdf

Version: 2024-02-01

		87888	106344
123	4,969	38	65
papers	citations	h-index	g-index

124	124	124	4981
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MRI contrast agents: Basic chemistry and safety. Journal of Magnetic Resonance Imaging, 2012, 36, 1060-1071.	3.4	249
2	Safety of approved MR contrast media for intravenous injection. Journal of Magnetic Resonance Imaging, 2000, 12, 205-213.	3.4	244
3	MR imaging of tumor microcirculation: Promise for the new millenium. Journal of Magnetic Resonance Imaging, 1999, 10, 903-907.	3.4	212
4	T1 Relaxivities of Gadolinium-Based Magnetic Resonance Contrast Agents in Human Whole Blood at 1.5, 3, and 7 T. Investigative Radiology, 2015, 50, 330-338.	6.2	192
5	Nephrogenic Systemic Fibrosis. Investigative Radiology, 2007, 42, 139-145.	6.2	191
6	Contrast Agents for Magnetic Resonance Imaging. Topics in Magnetic Resonance Imaging, 2003, 14, 426-435.	1.2	155
7	An Image-based Approach to Understanding the Physics of MR Artifacts. Radiographics, 2011, 31, 849-866.	3.3	145
8	Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents. Investigative Radiology, 2017, 52, 317-323.	6.2	144
9	Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus. Investigative Radiology, 2016, 51, 273-279.	6.2	127
10	A 3D Model of Human Cerebrovasculature Derived from 3T Magnetic Resonance Angiography. Neuroinformatics, 2009, 7, 23-36.	2.8	95
11	Primary and Secondary Brain Tumors at MR Imaging: Bicentric Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine. Radiology, 2004, 230, 55-64.	7.3	90
12	Safety of Magnetic Resonance Contrast Media. Topics in Magnetic Resonance Imaging, 2001, 12, 309-314.	1.2	86
13	High-dose gadoteridol in MR imaging of intracranial neoplasms. Journal of Magnetic Resonance Imaging, 1992, 2, 9-18.	3.4	83
14	Contrast Enhancement of Central Nervous System Lesions: Multicenter Intraindividual Crossover Comparative Study of Two MR Contrast Agents. Radiology, 2006, 240, 389-400.	7.3	83
15	Contrast-enhanced MR angiography. Journal of Magnetic Resonance Imaging, 1993, 3, 233-239.	3.4	79
16	Speed in Clinical Magnetic Resonance. Investigative Radiology, 2017, 52, 1-17.	6.2	78
17	The use of GD DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magnetic Resonance Imaging, 1985, 3, 43-55.	1.8	76
18	Simultaneous multi-slice readout-segmented echo planar imaging for accelerated diffusion-weighted imaging of the breast. European Journal of Radiology, 2016, 85, 274-278.	2.6	73

#	Article	IF	Citations
19	Brain Magnetic Resonance Imaging at 3 Tesla Using BLADE Compared With Standard Rectilinear Data Sampling. Investigative Radiology, 2006, 41, 586-592.	6.2	64
20	Gadolinium-Based MRI Contrast Agents Induce Mitochondrial Toxicity and Cell Death in Human Neurons, and Toxicity Increases With Reduced Kinetic Stability of the Agent. Investigative Radiology, 2019, 54, 453-463.	6.2	63
21	Analysis of Ischemic Stroke MR Images by Means of Brain Atlases of Anatomy and Blood Supply Territories. Academic Radiology, 2006, 13, 1025-1034.	2.5	60
22	SEMAC-VAT and MSVAT-SPACE Sequence Strategies for Metal Artifact Reduction in 1.5T Magnetic Resonance Imaging. Investigative Radiology, 2012, 47, 267-276.	6.2	60
23	Renal Arteries: Comparison of Steady-State Free Precession MR Angiography and Contrast-enhanced MR Angiography. Radiology, 2006, 239, 263-268.	7.3	59
24	A Historical Overview of Magnetic Resonance Imaging, Focusing on Technological Innovations. Investigative Radiology, 2012, 47, 725-741.	6.2	59
25	Dechelation (Transmetalation). Investigative Radiology, 2018, 53, 571-578.	6.2	56
26	A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis. Journal of Magnetic Resonance Imaging, 1999, 10, 15-24.	3.4	53
27	Local Tissue Toxicity in Response to Extravascular Extravasation of Magnetic Resonance Contrast Media. Investigative Radiology, 2002, 37, 393-398.	6.2	51
28	Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: Phase II clinical trial data. Journal of Magnetic Resonance Imaging, 1999, 9, 291-294.	3.4	50
29	A Clinical Comparison of the Safety and Efficacy of MultiHance (Gadobenate Dimeglumine) and Omniscan (Gadodiamide) in Magnetic Resonance Imaging in Patients with Central Nervous System Pathology. Investigative Radiology, 2001, 36, 65-71.	6.2	50
30	Initial clinical evaluation of gadolinium DTPA for contrast-enhanced magnetic resonance imaging. Magnetic Resonance Imaging, 1985, 3, 27-35.	1.8	49
31	Brain Tumor Enhancement in Magnetic Resonance Imaging. Investigative Radiology, 2005, 40, 792-797.	6.2	48
32	A Comparison of Two MR Hepatobiliary Gadolinium Chelates: Gd-BOPTA and Gd-EOB-DTPA. Journal of Computer Assisted Tomography, 1998, 22, 643-650.	0.9	48
33	Current Technological Advances in Magnetic Resonance With Critical Impact for Clinical Diagnosis and Therapy. Investigative Radiology, 2013, 48, 869-877.	6.2	46
34	Central Nervous System: Review of Clinical Use of Contrast Media. Topics in Magnetic Resonance Imaging, 2001, 12, 231-263.	1.2	42
35	The Efficacy of Gadobenate Dimeglumine (Gd-BOPTA) at 3 Tesla in Brain Magnetic Resonance Imaging. Investigative Radiology, 2006, 41, 244-248.	6.2	42
36	Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. Journal of Neurosurgery, 2007, 106, 557-566.	1.6	40

#	Article	IF	Citations
37	The Developmental History of the Gadolinium Chelates as Intravenous Contrast Media for Magnetic Resonance. Investigative Radiology, 2011, 46, 807-816.	6.2	40
38	Contrast-Enhanced 3-Dimensional SPACE Versus MP-RAGE for the Detection of Brain Metastases. Investigative Radiology, 2013, 48, 55-60.	6.2	40
39	Simultaneous Multislice Echo Planar Imaging With Blipped Controlled Aliasing in Parallel Imaging Results in Higher Acceleration. Investigative Radiology, 2015, 50, 456-463.	6.2	40
40	Contrast Enhanced MRI. Investigative Radiology, 1985, 20, 830-844.	6.2	39
41	Brain Tumor Enhancement in MR Imaging at 3 Tesla. Investigative Radiology, 2007, 42, 558-563.	6.2	38
42	Evaluation of a Modified Stejskal-Tanner Diffusion Encoding Scheme, Permitting a Marked Reduction in TE, in Diffusion-Weighted Imaging of Stroke Patients at 3 T. Investigative Radiology, 2010, 45, 29-35.	6.2	38
43	Advocating the Development of Next-Generation High-Relaxivity Gadolinium Chelates for Clinical Magnetic Resonance. Investigative Radiology, 2018, 53, 381-389.	6.2	36
44	High-dose applications of gadolinium chelates in magnetic resonance imaging. Magnetic Resonance in Medicine, 1991, 22, 358-363.	3.0	34
45	Principles of contrast enhancement in the evaluation of brain diseases: An overview. Journal of Magnetic Resonance Imaging, 1997, 7, 5-13.	3.4	34
46	Clinical comparison of three-dimensional MP-RAGE and FLASH techniques for MR imaging of the head. Journal of Magnetic Resonance Imaging, 1991, 1, 493-500.	3.4	33
47	Detectability of Early Brain Meningitis with Magnetic Resonance Imaging. Investigative Radiology, 1995, 30, 484-495.	6.2	33
48	Double-Blind, Efficacy Evaluation of Gadobenate Dimeglumine, a Gadolinium Chelate With Enhanced Relaxivity, in Malignant Lesions of the Brain. Investigative Radiology, 2002, 37, 269-280.	6.2	32
49	Magnetic Resonance Imaging of the Brain in Glutaric Acidemia Type I. Investigative Radiology, 2003, 38, 489-496.	6.2	30
50	Comparative Evaluation of Lesion Enhancement Using 1 M Gadobutrol vs. 2 Conventional Gadolinium Chelates, All at a Dose of 0.1 mmol/kg, in a Rat Brain Tumor Model at 3 T. Investigative Radiology, 2009, 44, 251-256.	6.2	30
51	Diffusion-Weighted Imaging in Patients With Acute Brain Ischemia at 3 T. Investigative Radiology, 2009, 44, 351-359.	6.2	30
52	Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: Comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T. Journal of Magnetic Resonance Imaging, 2010, 31, 549-555.	3.4	30
53	Advocating the Development of Next-Generation, Advanced-Design Low-Field Magnetic Resonance Systems. Investigative Radiology, 2020, 55, 747-753.	6.2	30
54	Magnetic Resonance Imaging of the Spine at 3 Tesla. Seminars in Musculoskeletal Radiology, 2008, 12, 238-252.	0.7	29

#	Article	IF	Citations
55	A Three-Dimensional Interactive Atlas of Cerebral Arterial Variants. Neuroinformatics, 2009, 7, 255-264.	2.8	29
56	Simulation and assessment of cerebrovascular damage in deep brain stimulation using a stereotactic atlas of vasculature and structure derived from multiple 3- and 7-tesla scans. Journal of Neurosurgery, 2010, 113, 1234-1241.	1.6	29
57	Recent Technological Advances in Computed Tomography and the Clinical Impact Therein. Investigative Radiology, 2015, 50, 119-127.	6.2	29
58	Diffusion Weighted Imaging. Investigative Radiology, 2009, 44, 656-661.	6.2	28
59	Commentary on T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats. Investigative Radiology, 2015, 50, 481-482.	6.2	28
60	Paramagnetic NMR Contrast Agents. Investigative Radiology, 1984, 19, 408-415.	6.2	27
61	MR Imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. Journal of Magnetic Resonance Imaging, 1994, 4, 669-673.	3.4	27
62	Off-label use and reimbursement of contrast media in MR. Journal of Magnetic Resonance Imaging, 1999, 10, 489-495.	3.4	27
63	Material-Dependent Implant Artifact Reduction Using SEMAC-VAT and MAVRIC. Investigative Radiology, 2017, 52, 381-387.	6.2	27
64	T1-Weighted Imaging of the Brain at 3 Tesla Using a 2-Dimensional Spoiled Gradient Echo Technique. Investigative Radiology, 2006, 41, 68-75.	6.2	26
65	A new presentation and exploration of human cerebral vasculature correlated with surface and sectional neuroanatomy. Anatomical Sciences Education, 2009, 2, 24-33.	3.7	26
66	Magnetic resonance angiography of the carotid arteries: comparison of unenhanced and contrast enhanced techniques. European Radiology, 2011, 21, 1667-1676.	4.5	26
67	Macrocyclic Versus Linear Gadolinium Chelates. Investigative Radiology, 2015, 50, 811.	6.2	25
68	Contrast-enhanced MR imaging of the liver. Journal of Magnetic Resonance Imaging, 1994, 4, 281-289.	3.4	24
69	Brain Tumor Enhancement in Magnetic Resonance Imaging at 3 Tesla. Investigative Radiology, 2009, 44, 200-206.	6.2	24
70	Optimization of spoiler gradients in flash MRI. Magnetic Resonance Imaging, 1987, 5, 455-463.	1.8	23
71	Phase II double-blind, dose-ranging clinical evaluation of gadobenate dimeglumine in focal liver lesions: With analysis of liver and kidney signal change on early and delayed imaging. Journal of Magnetic Resonance Imaging, 2000, 11, 655-664.	3.4	23
72	Advances in Clinical 3-Tesla Neuroimaging. Investigative Radiology, 2006, 41, 63-67.	6.2	23

#	Article	IF	Citations
73	Technical considerations in MR angiography: An imageâ€based guide. Journal of Magnetic Resonance Imaging, 2013, 37, 1326-1341.	3.4	23
74	Magnetic Resonance Imaging and Computed Tomography of the Brainâ€"50 Years of Innovation, With a Focus on the Future. Investigative Radiology, 2015, 50, 551-556.	6.2	23
75	Repeat cerebral blood volume assessment with first-pass MR imaging. Journal of Magnetic Resonance Imaging, 1994, 4, 457-461.	3.4	22
76	The Use of MR Contrast in Neoplastic Disease of the Brain. Topics in Magnetic Resonance Imaging, 1995, 7, 137???157.	1.2	22
77	A Review of Contrast Media Research in 1999â€"2000. Investigative Radiology, 2001, 36, 123-130.	6.2	21
78	Motion in Magnetic Resonance. Investigative Radiology, 2019, 54, 383-395.	6.2	21
79	Contrast Media Research. Investigative Radiology, 1999, 34, 785.	6.2	19
80	Particulate oral NMR contrast agents. International Journal of Nuclear Medicine and Biology, 1985, 12, 37-42.	0.3	18
81	Fast imaging and other motion artifact reduction schemes: A pictorial overview. Magnetic Resonance Imaging, 1988, 6, 595-608.	1.8	18
82	Accelerated magnetic resonance diffusion tensor imaging of the median nerve using simultaneous multi-slice echo planar imaging with blipped CAIPIRINHA. European Radiology, 2016, 26, 1921-1928.	4.5	18
83	Gadolinium and Nephrogenic Systemic Fibrosis. American Journal of Roentgenology, 2009, 192, W195-W196.	2.2	17
84	Magnetic Resonance Evaluation of Renal Artery Stenosis in a Swine Model. Investigative Radiology, 2012, 47, 376-382.	6.2	17
85	The Clinical Utility of Magnetic Resonance Imaging According to Field Strength, Specifically Addressing the Breadth of Current State-of-the-Art Systems, Which Include 0.55 T, 1.5 T, 3 T, and 7 T. Investigative Radiology, 2022, 57, 1-12.	6.2	17
86	Allergic Reactions to Gadolinium Chelates. American Journal of Roentgenology, 2001, 177, 944-945.	2.2	16
87	T1-Weighted Brain Imaging With a 32-Channel Coil at 3T Using TurboFLASH BLADE Compared With Standard Cartesian k-Space Sampling. Investigative Radiology, 2009, 44, 177-183.	6.2	15
88	Brain MRI With Single-Dose (0.1 mmol/kg) Gadobutrol at 1.5 T and 3 T: Comparison With 0.15 mmol/kg Gadoterate Meglumine. American Journal of Roentgenology, 2010, 194, 1337-1342.	2.2	15
89	Evaluation of Gadodiamide Versus Gadobutrol for Contrast-Enhanced MR Imaging in a Rat Brain Glioma Model at 1.5 and 3 T. Investigative Radiology, 2010, 45, 810-818.	6.2	14
90	Evaluation of Gadolinium 2,5-BPA-DO3A, a New Macrocyclic Hepatobiliary Chelate, in Normal Liver and Metastatic Disease on High Field Magnetic Resonance Imaging. Investigative Radiology, 1996, 31, 11-16.	6.2	13

#	Article	IF	Citations
91	Synthesis, Characterization, and Imaging Performance of a New Class of Macrocyclic Hepatobiliary MR Contrast Agents. Investigative Radiology, 2000, 35, 8.	6.2	13
92	Phase III clinical evaluation of Gd-HP-DO3A in head and spine disease. Journal of Magnetic Resonance Imaging, 1991, 1, 47-56.	3.4	12
93	Notes on â€œCharacteristics of Gadolinium-DTPA Complex: A Potential NMR Contrast Agentâ€• American Journal of Roentgenology, 2008, 190, 1433-1434.	2.2	12
94	Advances in Diagnostic Radiology. Investigative Radiology, 2010, 45, 823-826.	6.2	12
95	Evaluation of a Fibrin-Binding Gadolinium Chelate Peptide Tetramer in a Brain Glioma Model. Investigative Radiology, 2011, 46, 169-177.	6.2	12
96	Primary glioma: diagnosis with magnetic resonance imaging. The Journal of Computed Tomography, 1986, 10, 325-334.	0.1	11
97	Brain Tumor Enhancement in Magnetic Resonance Imaging. Investigative Radiology, 2009, 44, 89-94.	6.2	11
98	Detectability of Small Liver Metastases with Gadolinium BOPTA. Investigative Radiology, 1997, 32, 557-565.	6.2	11
99	The prospective evaluation of Gd-DTPA in 225 consecutive cranial cases: Adverse reactions and diagnostic value. Magnetic Resonance Imaging, 1990, 8, 381-393.	1.8	10
100	MR Angiography of the Renal Arteries: Intraindividual Comparison of Double-Dose Contrast Enhancement at 1.5 T with Standard Dose at 3 T. American Journal of Roentgenology, 2008, 190, 173-177.	2.2	10
101	Efficacy and safety of gadopentetate dimeglumine in the evaluation of patients with a suspected tumor of the extracranial head and neck. Journal of Magnetic Resonance Imaging, 1993, 3, 345-349.	3.4	9
102	Comparison of Gadolinium Cy2DOTA, a New Hepatobiliary Agent, and Gadolinium HP-DO3A, an Extracellular Agent, in Healthy Liver and Metastatic Disease. Investigative Radiology, 1995, 30, 123-130.	6.2	9
103	Subchronic Toxicity of the Gadolinium Chelates. Academic Radiology, 2005, 12, S6-S9.	2.5	8
104	The Protein and Contrast Agentâ€“Specific Influence of Pathological Plasma-Protein Concentration Levels on Contrast-Enhanced Magnetic Resonance Imaging. Investigative Radiology, 2014, 49, 608-619.	6.2	7
105	A novel diagnostic method (spectral computed tomography of sacroiliac joints) for axial spondyloarthritis. Journal of the Formosan Medical Association, 2016, 115, 658-664.	1.7	7
106	Choice of Metal Ion and Formulation Concentration for First-Pass Brain Perfusion Studies with Magnetic Resonance Imaging at 1.5 Tesla. Investigative Radiology, 1996, 31, 395-400.	6.2	7
107	Gadoteridol dose dependence in MR imaging of a liver abscess model. Journal of Magnetic Resonance Imaging, 1994, 4, 343-350.	3.4	6
108	Magnetization Transfer and High-Dose Contrast in Early Brain Infection on Magnetic Resonance. Investigative Radiology, 1995, 30, 135-143.	6.2	6

#	Article	IF	Citations
109	In vitro T2 relaxivities of the Gd-based contrast agents (GBCAs) in human blood at 1.5 and 3 T. Acta Radiologica, 2019, 60, 694-701.	1.1	6
110	Magnetic Resonance Imaging of an Experimental Model of Intracranial Metastatic Disease. Investigative Radiology, 1994, 29, 1050-1056.	6.2	5
111	Scientific Advances, Investigative Radiology 2020 (and Beyond). Investigative Radiology, 2021, 56, 271-273.	6.2	5
112	Contrast Media Research. Investigative Radiology, 2002, 37, 643-646.	6.2	3
113	Advances in Magnetic Resonance (2006). Investigative Radiology, 2006, 41, 904-909.	6.2	3
114	Advances in Magnetic Resonance (2008). Investigative Radiology, 2008, 43, 893-898.	6.2	3
115	Trends in Contrast Media Research. Investigative Radiology, 2001, 36, 688-691.	6.2	3
116	Magnetic Resonance Research. Investigative Radiology, 2003, 38, 802-805.	6.2	2
117	Advances in Magnetic Resonance (2007). Investigative Radiology, 2007, 42, 862-867.	6.2	2
118	Advances in Magnetic Resonance (2009). Investigative Radiology, 2009, 44, 808-812.	6.2	2
119	The Question of Dose for Gadolinium Chelates in Magnetic Resonance Imaging. Investigative Radiology, 1994, 29, S154-S156.	6.2	1
120	Changes in the approval process for contrast media. Journal of Magnetic Resonance Imaging, 1999, 10, 485-488.	3.4	1
121	Advances in Magnetic Resonance. Investigative Radiology, 2004, 39, 713-716.	6.2	1
122	Advances in Magnetic Resonance (2005). Investigative Radiology, 2005, 40, 798-802.	6.2	1
123	Fifty Years of the Best of Investigative Radiology. Investigative Radiology, 2015, 50, 549-550.	6.2	0